 Juan Monteverde, founder and managing partner at Monteverde Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Pfenex Inc. PFNX or the Company NYSE American: PFNX relating to its sale to Ligand Pharmaceuticals Incorporated. Under the terms of the agreement, PFNX shareholders will receive 12.00 in cash for each share of PFNX stock owned. 